Want to see GANX full AI Analyst Report?
Total Valuation
Gain Therapeutics has a market cap or net worth of $86.41M. The enterprise value is $74.57.
Market Cap$86.41M
Enterprise Value$74.57
Share Statistics
Gain Therapeutics has 43,643,620 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding43,643,620
Owned by Insiders2.23%
Owned by Institutions3.85%
Financial Efficiency
Gain Therapeutics’s return on equity (ROE) is -1.09 and return on invested capital (ROIC) is -95.04%.
Return on Equity (ROE)-1.09
Return on Assets (ROA)-0.88
Return on Invested Capital (ROIC)-95.04%
Return on Capital Employed (ROCE)-0.96
Revenue Per Employee0.00
Profits Per Employee-960.05K
Employee Count21
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Gain Therapeutics is ―. Gain Therapeutics’s PEG ratio is 0.17.
PE Ratio―
PS Ratio0.00
PB Ratio5.72
Price to Fair Value5.72
Price to FCF-5.75
Price to Operating Cash Flow-4.54
PEG Ratio0.17
Income Statement
In the last 12 months, Gain Therapeutics had revenue of 0.00 and earned -20.16M in profits. Earnings per share was -0.61.
Revenue0.00
Gross Profit0.00
Operating Income-18.71M
Pretax Income-19.30M
Net Income-20.16M
EBITDA-19.21M
Earnings Per Share (EPS)-0.61
Cash Flow
In the last 12 months, operating cash flow was -18.95M and capital expenditures -5.00, giving a free cash flow of -18.95M billion.
Operating Cash Flow-18.95M
Free Cash Flow-18.95M
Free Cash Flow per Share-0.43
Dividends & Yields
Gain Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.90
52-Week Price Change8.97%
50-Day Moving Average1.83
200-Day Moving Average2.20
Relative Strength Index (RSI)55.60
Average Volume (3m)1.07M
Important Dates
Gain Therapeutics upcoming earnings date is Nov 18, 2026, After Close (Confirmed).
Last Earnings DateAug 11, 2026
Next Earnings DateNov 18, 2026
Ex-Dividend Date―
Financial Position
Gain Therapeutics as a current ratio of 6.63, with Debt / Equity ratio of 5.40%
Current Ratio6.63
Quick Ratio6.63
Debt to Market Cap<0.01
Net Debt to EBITDA1.05
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Gain Therapeutics has paid 861.12K in taxes.
Income Tax861.12K
Effective Tax Rate-0.04
Enterprise Valuation
Gain Therapeutics EV to EBITDA ratio is -4.48, with an EV/FCF ratio of -4.66.
EV to Sales0.00
EV to EBITDA-4.48
EV to Free Cash Flow-4.66
EV to Operating Cash Flow-4.66
Balance Sheet
Gain Therapeutics has $13.08M in cash and marketable securities with $609.87K in debt, giving a net cash position of $12.47M billion.
Cash & Marketable Securities$13.08M
Total Debt$609.87K
Net Cash$12.47M
Net Cash Per Share$0.29
Tangible Book Value Per Share$0.56
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Gain Therapeutics is $7.20, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$7.20
Price Target Upside311.43% Upside
Analyst ConsensusStrong Buy
Analyst Count5
Revenue Growth Forecast―
EPS Growth Forecast23.02%